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Table 1. Patient and Product Characteristics
Transplant Variable
Ethnically
Matched
Ethnically
Mismatched
Ethnic Group
Recipient Donor
Caucasian Caucasian 97.1%
Poster Session II S353can aid in the early detection of relapsing leukemia, especially when
leukemia-specific mutation assays are not available. Detection of in-
creasing recipient-origin (mixed) chimerism may be useful in deci-
sions to alter immunosuppression, to administer donor lymphocyte
infusions, or for other treatment changes.
Previous reports showed complete chimerism correlated well with
overall survival and negatively with relapse probability. In the U.S.,
detection of chimerism is performed using PCR for variable number
or short tandem repeats, followed by fragment separation by capil-
lary electrophoresis, resulting in poor sensitivity below 10% recipi-
ent DNA due to the imprecision of measurements of areas under the
peaks in fragment separation, as well as problematic stutter artifacts.
The higher sensitivity of detection of chimerism provided by the
real-time PCR assay could be beneficial in allowing for earlier detec-
tion of increasingmixed chimerismwith the proviso that the assay be
performed at an optimal frequency for the underlying type of
leukemia.
Previous real-time PCR assays for chimerism were not able to de-
tect an informative marker for the ‘‘recipient’’ in all ‘‘donor/recipi-
ent’’ pairs due to insufficient numbers of markers. Our assay of 28
marker loci detected at least one informative marker (IM) in 754 of
756 directional combinations of DNAs (99.7%), with an average of
5.1 markers per pair. In a subset of 28 first-degree relative pairs,
one or more IMs were found in 27 pairs (96.4%), with an average
of 3.5 IM/pair. Linearity of markers was examined by dilution of
DNA from an IM+ donor in IM-DNA. All markers showed linearity
with good PCR efficiency values. A single copy gene was used for
normalizing the % chimerism with a DDCt method using simulated
post-transplant samples (mixtures of DNAs) relative to the pre-
transplant samples (100% recipient DNAs). The % chimerism cal-
culated from DNA dilution series showed linearity with precision
down to at least 0.1% recipient DNA. The calculated % chimerism
was compared to the nominal value for determinations of accuracy
and equivalence of readout between different markers. Inter-assay
variability over three days and between three markers was demon-
strated to meet acceptance criteria.African American African American 2.2%
Asian Asian 0.6%
Hispanic/Latino Hispanic/Latino 0.2%
Caucasian Other 10.9%
Asian Other 8.2%
African American Other 26.6%
Hispanic/Latino Other 52.7%
Multi-Race Other 1.6%
Transplant Type
Single 477 161
Dual 47 8
HLA Match*
<5/6 168 86
$5/6 356 83
Gender*
Male 271 105
Female 242 61
Patient Age
N 524 169
Median (y) 7.8 6.2
Patient Weight
N 524 169
Median (kg) 25.6 21.5
TBI
Yes 264 81
No 231 75
Conditioning Regimen*
Non-Myeloablative 139 71
Myeloablative 365 94
TNC Dose
N 525 169
Median (107/kg) 6.4 6.8
CD34 Dose
N 521 168
Median (105/kg) 2.6 3.0
CFU Dose
N 521 168
Median (105/kg) .39 .39
*Denotes p values <.05.403
SURVIVAL AFTER ALLOGENEIC TRANSPLANT FOR RELAPSED LEUKEMIA
FOLLOWING CYCLOPHOSPHAMIDE, ETOPOSIDE, AND TOTAL BODY RA-
DIATION (TBI) WITH LUNG SHIELDING: INFLUENCE OF cGVHD ON RE-
LAPSE AND LUNG SHIELDING ON PULMONARY COMPLICATIONS
Morris, J.1, Morris, C.L.1, Loredo, L.2 1Loma Linda University Medical
Center, Loma Linda, CA; 2Loma Linda UniversityMedical Center, Loma
Linda, CA
Background: High dose chemotherapy and allogenic stem cell
transplant is used to consolidate relapsed leukemia. GVT is an im-
portant component of curing leukemia in this setting and GVHD
and TBI are important causes of toxicity, most notably late lung
complications. We have employed lung shielding to reduce pulmo-
nary complications in long term survivors of SCT.We report the im-
pact of cGVHD on relapse and the incidence of late lung
complications in these patients.
Method: Thirty-three patients with ALL (24), AML (8), and NHL
(1) in CR2 (28), and . or equal to CR3 (5) received allogeneic
PBSCT. Graft source was unrelated (20), HLA mismatched related
(1), or HLA identical sibling donor (12). All received 1200 cGy TBI,
etoposide 1500mg/m2, and cyclophosphamide 120mg/kg. Unre-
lated or mismatched related stem cell recipients also received ATG
(90mg/kg over 3 days). TBI was delivered in 200cGy fractions twice
daily for 3 days with double lung blocks to reduce lung dose to
300cGy. The chest wall was boosted with electrons to 1200cGy.
GVHD prophylaxis was cyclosporin for matched siblings or tacroli-
mus (all others) and short course methotrexate (10mg/M2 days 1, 3,
6, and 11 except 1 recipient of cord blood who received steroids).
Result:OS andDFSwere 19/33 (actuarial 53%) and 17/33 with me-
dian time from transplant of 41 and 47 months. For patients.1 and
.4 years from transplant, TRMwas 4/28 at 1 year and 4/15 at year 4.
Relapse for patients.1 year from transplant was 7/28 (6/11matched
sibling, 1/16 unrelated, 0/1 mismatched related donor). All relapses
occurred\1 year after transplant except 1 (21 month). The relapse
rate for sibling transplants complicated by cGVHD was 0/4 (all sur-
vived at least 1 year) and was 6/7 for sibling transplants with nocGVHD. The relapse rate for recipients of unrelated PBSC grafts
was 1/12 with 10/12 complicated by cGVHD. Of the 14 patients
with cGVHD it has resolved in 4, requires continued treatment in
5, 2 died of complications from cGVHD, and 1 relapse. There was
one case of idiopathic pneumonitis in a sibling donor transplant oc-
curring within 50 days of transplant. Among 20 patients surviving at
.1 year after transplant there is 1 case of severe restrictive lung dis-
ease due to chest wall contractures from cGVHD.
Conclusion: 1. The best predictor of DFS in this series was presence
of cGVHD. 2. GVHD was the strongest predictor of TRM. 3. Late
pulmonary complications were rare.
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EFFECTIVENESS OF UNRELATED ALLOGENEIC UMBILICAL CORD BLOOD
TRANSPLANTATION FOR ETHNICALLY MATCHED AND MISMATCHED PA-
TIENT POPULATIONS
Wofford, J.1, Sander, J.1, Stocker, A.1, Regan, D.1, Bhatla, D.2 1The St.
Louis Cord Blood Bank, St. Louis, MO; 2St. Louis University School of
Medicine, St. Louis, MO
Allogeneic hematopoietic stem cell transplantation (HSCT) has
become the accepted treatment for many life threatening hemato-
logic diseases. Outcomes are superior when HLA matched related
donors are the stem cell source for allogeneic HSCT. However,
only 15-20% of patients needing a marrow or blood cell transplant
